James Basta, EVP and General Counsel at Intellia Therapeutics ($NTLA), sold shares on the open market twice in the last year, totaling about $112 thousand. His most recent sale occurred on March 2, 2026. These sales rank 9,397th among 11,678 insiders, well below the average of $8.6 million per seller and 6.4 transactions. Basta made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | S | Common Stock | 1211 | $13.78 | 156,794.0000 | 115,829,926 | 0.77% | 0.00% |
| March 1, 2026 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | A | Common Stock | 46080 | $0.00 | 158,005.0000 | 115,829,926 | 41.17% | 0.04% |
| March 1, 2026 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | A | Stock Option (right to buy) | 65829 | $0.00 | 65,829.0000 | 115,829,926 | 9999.99% | 0.06% |
| Jan. 5, 2026 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | S | Common Stock | 10397 | $9.21 | 101,528.0000 | 115,829,926 | 9.29% | 0.01% |
| March 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | A | Common Stock | 40000 | $0.00 | 114,497.0000 | 103,517,460 | 53.69% | 0.04% |
| March 4, 2025 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | S | Common Stock | 2572 | $8.99 | 111,925.0000 | 103,517,460 | 2.25% | 0.00% |
| March 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | A | Stock Option (right to buy) | 57143 | $0.00 | 57,143.0000 | 103,517,460 | 9999.99% | 0.06% |
| Jan. 3, 2025 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | S | Common Stock | 7074 | $12.18 | 74,497.0000 | 0 | 8.67% | 0.00% |
| March 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | A | Stock Option (right to buy) | 46752 | $0.00 | 46,752.0000 | 0 | 9999.99% | 0.00% |
| March 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | A | Common Stock | 32394 | $0.00 | 83,868.0000 | 0 | 62.93% | 0.00% |
| March 4, 2024 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | S | Common Stock | 2297 | $32.99 | 81,571.0000 | 0 | 2.74% | 0.00% |
| Jan. 3, 2024 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | S | Common Stock | 3805 | $29.46 | 51,474.0000 | 0 | 6.88% | 0.00% |
| March 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | A | Stock Option (right to buy) | 34674 | $0.00 | 34,674.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2023 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | S | Common Stock | 1088 | $43.88 | 55,279.0000 | 0 | 1.93% | 0.00% |
| March 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | A | Common Stock | 12269 | $0.00 | 56,367.0000 | 0 | 27.82% | 0.00% |
| March 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | A | Common Stock | 24539 | $0.00 | 44,098.0000 | 0 | 125.46% | 0.00% |
| Jan. 4, 2023 | Intellia Therapeutics, Inc. | $NTLA | BASTA JAMES | EVP, General Counsel | S | Common Stock | 1138 | $37.21 | 19,559.0000 | 0 | 5.50% | 0.00% |